Ocata Therapeutics of Marlborough has secured another patent for its technology aimed at treating some forms of macular degeneration, the company announced last week.
Ocata’s most advanced products, focusing on retinal pigment epithelium (RPE) transplant technology, are in clinical trials for the treatment of Stargardt’s macular degeneration, dry age-related macular degeneration, and myopic macular degeneration, according to the company, formerly known as Advanced Cell Technology.
It’s the ninth patent for the company’s RPE portfolio, according to Ocata’s president and CEO, Paul K. Wotton.
Within the last two months, Ocata received three other patents for its technology, and issued a $30 million stock offering.
